NCT04248439View on ClinicalTrials.gov

Gene Therapy for Fanconi Anemia, Complementation Group A

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

July 15, 2020

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2026

Conditions
Fanconi Anemia Complementation Group A
Interventions
BIOLOGICAL

RP-L102

CD34+ enriched cells from subjects with Fanconi anemia subtype A transduced ex vivo with a lentiviral vector carrying the FANCA gene

Trial Locations (2)

55454

University of Minnesota, Minneapolis

94304

Stanford University, Stanford

All Listed Sponsors
lead

Rocket Pharmaceuticals Inc.

INDUSTRY